Nov 9, 2021
Mike Gladstone is the Global President of Inflammation & Immunology at Pfizer. We talk about conditions such as rheumatoid arthritis, irritable bowel syndrome (IBS), and atopic dermatitis (AD) and how minority patients with these conditions are often misdiagnosed.
Mike explains, "Well, it turns out that a lot of these diseases are completely unseen, or those diseases that are seen are just not well understood. And the reason why is, for instance, if I look at someone suffering from atopic dermatitis, for example, you may see some of the symptoms that they have, and those are bad enough, some of the redness and scratching and so forth. But what you don't know and what you don't see is how the patients suffer sometimes. They have the stares from others, they feel those stares, they feel the distance. They feel the judgment from others who see their condition, but it also goes much deeper than that. What you don't see for those patients is the constant itching."
"Now, Black and Hispanic children are also more likely than White children to miss school because of AD, and they're likely to report uncontrolled or longer duration AD. And despite the prevalence of skin conditions like this with minority individuals, they're underrepresented in medical dermatology textbooks and clinical research."
@Pfizer #ChronicConditions #AtopicDermatitis #Dermatology #HealthEquity #HealthInnovation #DigitalHealth #AFib